Celcuity Secures FDA Nod for REVTORPYK in HR+/HER2- Breast Cancer
Event summary
- FDA approves REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA wild-type advanced breast cancer on July 14, 2026.
- Phase 3 VIKTORIA-1 trial shows 76% and 67% reduction in disease progression or death with REVTORPYK combinations vs. fulvestrant alone.
- Celcuity plans Q3 2026 commercial launch and sNDA submission for PIK3CA-mutated breast cancer indication.
The big picture
Celcuity's FDA approval marks a breakthrough in targeting the PI3K/AKT/mTOR pathway, addressing a longstanding challenge in oncology. The approval positions REVTORPYK as a first-in-class therapy for HR+/HER2- breast cancer, potentially capturing a significant share of the 60% of patients without PIK3CA mutations. Success hinges on Celcuity's ability to navigate commercialization and expand regulatory approvals globally.
What we're watching
- Commercialization Strategy
- The pace at which Celcuity can scale REVTORPYK's commercial launch and patient access programs.
- Regulatory Expansion
- Whether the sNDA submission for PIK3CA-mutated breast cancer will succeed, broadening market potential.
- Clinical Pipeline Progress
- How ongoing Phase 3 VIKTORIA-2 and CELC-G-201 trials may extend REVTORPYK's therapeutic reach.
Related topics